Singapore, Aug. 5 -- The Health Sciences Authority received information related to the study titled 'A Global, Multicentre, Phase II Platform Study of Datopotamab Deruxtecan (Dato-DXd)-based Combinations in Adult Participants With TROP2 NMR-positive Non-small Cell Lung Cancer (NSCLC) (PATAGONIA)'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
Curie Oncology (Farrer)
National Cancer Centre
National University Hospital
Tan Tock Seng Hospital
Trial Status: NA
Principal Investigator(s):
Dr Toh Chee Keong
Dr Stephanie Saw
Dr Ross Soo
Dr Chia Puey Ling
Published by HT Digital Content Services with permission from Health Daily Digest....